20 completed, 3 withdrawn, 2 active not recruiting, 2 terminated. 13 Phase 1, 9 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Ovarian Serous Cystadenocarcinoma: new trials by email Literature Review of Ovarian Serous Cystadenocarcinoma trials Research Report on Ovarian Serous Cystadenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors ZB131 - Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma | Phase 1 / Phase 2 | Completed | ZielBio, Inc. | 35 | 2022-01-14 | 2024-01-29 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Everolimus, Laboratory Biomarker Analysis, Letrozole - Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Completed | Mayo Clinic | 20 | 2014-11-14 | 2020-10-23 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-09-10 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2014-05-20 | 2026-08-28 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 16 | 2012-07-09 | 2019-03-12 |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2011-10-11 | 2019-07-22 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin belinostat, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2009-12-01 | 2019-07-23 |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | University of Washington | 21 | 2006-05-01 | 2017-08-28 |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis - Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma | Phase 1 | Completed | University of Washington | 11 | 2005-04-01 | 2019-05-14 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer adjuvant therapy, paclitaxel, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 113 | 2004-06-01 | 2019-07-22 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2019-07-22 |
Showing 20 of 27. Sign in to see all of them.
Fallopian Tube Neoplasms (23) · Ovarian Neoplasms (18) · Brenner Tumor (17) · Carcinoma, Ovarian Epithelial (9) · Neurotoxicity Syndromes (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Dysgerminoma (1) · Fatigue (1) · Gestational Trophoblastic Disease (1) · Glioblastoma (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Nausea (1) · Neoplasms (1)
Adnexal Diseases (27) · Endocrine Gland Neoplasms (27) · Endocrine System Diseases (27) · Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Genital Diseases (27) · Genital Diseases, Female (27) · Genital Neoplasms, Female (27) · Gonadal Disorders (27) · Neoplasms by Site (27) · Ovarian Diseases (27) · Urogenital Diseases (27) · Urogenital Neoplasms (27) · Neoplasms (26) · Fallopian Tube Diseases (23)
Carboplatin (10) · Taxes (9) · Paclitaxel (8) · Bevacizumab (4) · Cisplatin (3) · Chemotherapy, Adjuvant (2) · Disulfides (2) · Doxorubicin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Immunoglobulin G (2) · Metformin (2) · Topotecan (2) · liposomal doxorubicin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1)
Gynecologic Oncology Group (11) · National Cancer Institute (NCI) (9) · Mayo Clinic (2) · University of Washington (2) · Fox Chase Cancer Center (1) · University of Chicago (1) · ZielBio, Inc. (1)
United States (26) · Canada (1) · Japan (1) · Singapore (1)
Don Dizon (3) · Mark Morgan (2) · Amit M Oza (1) · Angela Jain (1) · Barbara Goff (1) · Bradley Monk (1) · David Gershenson (1) · David Kushner (1) · Deborah Armstrong (1) · Gerardo Colon-Otero (1) · Joan Walker (1) · Lakshmi Nayak (1) · Lisa Hess (1) · Lisa Landrum (1) · Lupe Salazar (1)
PMID 20837357, PMID 28341300, PMID 33485453, PMID 39362046
U10CA027469 (12), U10CA180868 (4), U10CA101165 (3), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P30CA006516 (1), P30CA006927 (1), P30CA015083 (1), P50CA136393 (1), U01CA062490 (1), U01CA076576 (1), U10CA180821 (1), UM1CA186644 (1)